ArticleIBRO neuroscience reports2026
Dengzhanxixin injection for acute ischemic stroke after reperfusion therapy: A double-blind, placebo-controlled, multi-center clinical trial.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Revascularization for acute ischemic stroke (AIS) can salvage at-risk brain tissue, but reperfusion injury may reduce their benefits. This study aims to evaluate the efficacy and safety of Dengzhanxixin (DZXX) injection in AIS patients receiving reperfusion therapy. Methods: The DAISY (Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion TherapY) is a multicenter, randomized, double-blind, placebo-controlled, dose-exploration clinical trial. AIS patients who received reperfusion therapy were randomly assigned in a 1:1:1 ratio: high-dose (80 mg per day) DZXX injection, low-dose (40 mg per day) DZXX injection, and placebo, for 10-14 consecutive days. The primary efficacy outcome was the proportion of participants with modified Rankin Scale (mRS) score (0-1) at 90 days. The safety outcome was any adverse event within 90 days after treatment. Results: Between September 2022 and August 2023, a total of 246 patients from 17 centers were enrolled, with 78 assigned to high-dose group, 89 to low-dose group, and 79 to placebo group. At 90-days, the proportion of participants with a mRS score of 0 or 1 was 78.21 % in high-dose, 77.53 % in low-dose, and 65.82 % in placebo (high-dose Conclusion: DZXX injection demonstrated a trend toward improved functional outcomes at 90-days, but the differences were not statistically significant. It would be safe for patients with AIS undergoing reperfusion therapy without increasing the risk of bleeding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.